| 查看: 411 | 回复: 0 | ||
西点6688木虫 (正式写手)
|
[求助]
各位大神，求助一段话的翻译，谢谢！~荟萃分析
|
|
RESULT We summarized 20 trials carried out in metastatic melanoma (MM), non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC) patients receiving anti-PD-1/PD-L1 antibodies (4230 MM, 1417 NSCLC and 312 RCC patients). Positive PD-L1 MM patients showed a significant decrease (53%) in the risk of mortality vs. negative cases with no heterogeneity. Furthermore, SORRs were 45% and 27% in PD-L1 positive and negative patients, respectively, and SOR indicates a significant difference in term of responses: 2.14 (95% CI: 1.65, 2.77), with low between-study heterogeneity (I2= 35%). Furthermore, results from randomized clinical trials on MM showed that PD-L1 expression is significantly associated with greater clinical response rates to anti-PD1 treatments (SOR 1.89; 95%CI: 1.35, 2.64) but not to other treatments (SOR 0.96; 95%CI: 0.5, 1.87). 因为是荟萃学分析，有些术语不理解，望专业人士点播，谢谢！原文网址： https://www.ncbi.nlm.nih.gov/pubmed/26895815 |
回复此楼» 猜你喜欢
274求调剂
已经有4人回复
-
328求调剂，英语六级551，有科研经历
已经有10人回复
-
328求调剂，英语六级551，有科研经历
已经有7人回复
-
材料专业求调剂
已经有5人回复
-
一志愿天津大学化学工艺专业（081702）315分求调剂
已经有10人回复
-
344求调剂
已经有7人回复
-
一志愿985，本科211，0817化学工程与技术319求调剂
已经有7人回复
-
271材料工程求调剂
已经有4人回复
-
材料专硕英一数二306
已经有4人回复
-
294求调剂材料与化工专硕
已经有4人回复
5